ArticleAnnals of nuclear medicine2026
Baseline PSMA-ligand PET/CT as a predictive biomarker for early progression in metastatic castration-resistant prostate cancer patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy.
Baptiste Mercier et al.PubMed ↗Publisher ↗
No numbers read from the abstract.